Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

6.550 -0.050 (-0.76%)
Delayed Quote Updated: 1:21 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period ↗
Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of... 
Via Benzinga
News headline image
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Is IN8bio (INAB) Stock Up 9% Today? ↗
IN8bio (INAB) stock is rising higher on Wednesday as the biopharmaceutical company's shares continue their wild swings this week. 
Via InvestorPlace
News headline image
Why DXC Technology Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket ↗
Gainers Monogram Orthopaedics Inc. (NASDAQ: MGRM) shares surged 163.7% to $30.98 in pre-market trading after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of... 
Via Benzinga
News headline image
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
News headline image
Benzinga Pro's Top 5 Stocks To Watch For Friday, May 12, 2023: CMCSA, KR, ON, TSVT, CMND ↗
Comcast (CMCSA) - The parent company of NBCUniversal. One of Friday's most-discussed stories stemmed from a tweet by Elon Musk he had found a new exec to file the chief exec role at Twitter. 
Via Benzinga
News headline image
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment ↗
Clearmind Medicine Inc. 
Via Benzinga
News headline image
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
News headline image
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction ↗
Alcohol Use Disorder (AUD) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine (NASDAQ: CMND), the Israel-based company is going at it through its... 
Via Benzinga
News headline image
Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
News headline image
Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Meta Platforms Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Why Chipotle Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 105% to $0.1730 after the company issued a letter to shareholders. 
Via Benzinga
News headline image
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 46% Today? ↗
ZyVersa Therapeutics (ZVSA) stock is sliding lower on Wednesday following a couple of announcements from the biopharmaceutical company. 
Via InvestorPlace
News headline image
Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Why Is Clearmind Medicine (CMND) Stock Up 45% Today? ↗
Clearmind Medicine (CMND) stock is taking off on Wednesday even without any recent news from the psychedelic medicine company. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time for another dive into the biggest pre-market stock movers that investors need to know about on Wednesday morning! 
Via InvestorPlace
News headline image
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
News headline image
SciSparc And Clearmind Collaboration Strengthens IP Portfolio With Patent Application For Treatment Of Depression ↗
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
News headline image
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
From SciSparc Ltd
Via GlobeNewswire
News headline image
Psyched Clinical Trials: Australian Univ. Pursues MDMA, MEAI Compound About To Set Off ↗
Monash University Engages LaNeo MDMA Australian Monash University’s psychedelics research lab has contracted MDXX-class molecules developer PharmAla Biotech to manufacture and supply its clinical-grade... 
Via Benzinga
News headline image
Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its previously proposed registered direct offering. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.